Ocular cystinosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:411641OMIM:219750E72.0
Who is this for?
Show terms as
1FDA treatments2Active trials17Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Ocular cystinosis, also called non-nephropathic cystinosis or benign cystinosis, is a rare inherited metabolic disorder that affects the eyes. It is the mildest form of cystinosis, a group of conditions caused by the buildup of an amino acid called cystine inside cells. In ocular cystinosis, cystine crystals accumulate mainly in the cornea (the clear front part of the eye), while the kidneys and other organs are typically spared. This sets it apart from the more severe infantile (nephropathic) form of cystinosis, which causes serious kidney damage early in life. People with ocular cystinosis usually develop symptoms in late childhood, adolescence, or adulthood. The hallmark sign is the presence of cystine crystals in the cornea, which can cause light sensitivity (photophobia), eye irritation, tearing, and sometimes a feeling of grittiness in the eyes. Vision may be mildly affected over time, but many individuals maintain good overall eyesight. Because the disease is limited to the eyes, people with this form generally have a normal lifespan and do not develop the kidney failure or growth problems seen in more severe types of cystinosis. Treatment focuses on managing eye symptoms. Cysteamine eye drops (brand name Cystaran or Cystadrops) are the main therapy and work by dissolving the cystine crystals in the cornea. These drops need to be used regularly throughout the day. Lubricating eye drops and sunglasses can also help with comfort. There is currently no cure, but with consistent treatment, symptoms can be well controlled.

Also known as:

Key symptoms:

Sensitivity to bright light (photophobia)Eye irritation or discomfortTearing or watery eyesGritty feeling in the eyesVisible crystals in the cornea on eye examMild blurring of visionEye rednessDifficulty with glare

Clinical phenotype terms (4)— hover any for plain English
Corneal crystalsHP:0000531Elevated leukocyte cystineHP:0032639
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

4 events
Jun 2025DFT383 in Pediatric Participants With Nephropathic Cystinosis

Novartis Pharmaceuticals — PHASE1

TrialRECRUITING
Apr 2019CYSTEA-BONE Clinical Study

Hospices Civils de Lyon — NA

TrialRECRUITING
Dec 2017

PROCYSBI: FDA approved

PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.

FDAcompleted
Aug 1994

Cystagon: FDA approved

Treatment of nephropathic cystinosis in adults and children.

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

PROCYSBI

cysteamine enteric coated· Horizon Therapeutics USA, Inc.Orphan Drug

PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.

Clinical Trials

2 recruitingView all trials with filters →
Phase 11 trial
DFT383 in Pediatric Participants With Nephropathic Cystinosis
Phase 1
Actively Recruiting Prior treatment eligible
PI: Novartis Pharmaceuticals · Sites: San Diego, California; Stanford, California +2 more · Age: 25 yrs
N/A1 trial
CYSTEA-BONE Clinical Study
N/A
Actively Recruiting
PI: Justine BACCHETTA, MD PhD · Sites: Besançon; Bordeaux +11 more · Age: 299 yrs

Specialists

17 foundView all specialists →
WA
Wissem Ben Azzouz
Specialist
1 Ocular cystinosis publication
JP
Justine BACCHETTA, MD PhD
Besançon
Specialist

Rare Disease Specialist

SF
Salima Ferchichi
Specialist
1 Ocular cystinosis publication
HT
Hadhami Ben Turkia
Specialist
1 Ocular cystinosis publication
NT
Neji Tebib
Specialist
1 Ocular cystinosis publication
TM
Taieb Massoud
Specialist
1 Ocular cystinosis publication
LC
Latifa Chkioua
Specialist
1 Ocular cystinosis publication
CS
Chaima Saheli
Specialist
1 Ocular cystinosis publication
WM
Wassila Mili
Specialist
1 Ocular cystinosis publication
SM
Sameh Mabrouk
Specialist
1 Ocular cystinosis publication
IC
Imen Chabchoub
Specialist
1 Ocular cystinosis publication
HB
Hela Boudabous
Specialist
1 Ocular cystinosis publication
RM
Rachel J Bishop, M.D.
Specialist
PI on 2 active trials
SS
Sapna Sharan
Specialist
1 Ocular cystinosis publication
JG
Joanne Grimmer
Specialist
1 Ocular cystinosis publication
IM
Inas Makar
Specialist
1 Ocular cystinosis publication
ET
Edward Tran
Specialist
1 Ocular cystinosis publication

Treatment Centers

8 centers
⚗️ Trial Site

Hôpital Femme Mère Enfant

📍 Bron

👤 Justine BACCHETTA, MD PhD

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

Financial Resources

1 resources
PROCYSBI(cysteamine enteric coated)Horizon Therapeutics USA, Inc.

Travel Grants

No travel grants are currently matched to Ocular cystinosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Ocular cystinosisForum →

No community posts yet. Be the first to share your experience with Ocular cystinosis.

Start the conversation →

Latest news about Ocular cystinosis

Disease timeline:

New trial: DFT383 in Pediatric Participants With Nephropathic Cystinosis

Phase PHASE1 trial recruiting. DFT383

New trial: CYSTEA-BONE Clinical Study

Phase NA trial recruiting. Blood sampling

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How severe are the cystine crystal deposits in my (or my child's) corneas right now?,How often do the cysteamine eye drops need to be used, and are there tips to make the schedule easier?,Do we need to test for kidney or other organ involvement to rule out more severe forms of cystinosis?,What genetic testing should family members consider, especially if we plan to have more children?,Are there any newer or longer-acting eye drop formulations available or in clinical trials?,How often should follow-up eye exams be scheduled?,What should I watch for that would indicate the condition is getting worse?

Common questions about Ocular cystinosis

What is Ocular cystinosis?

Ocular cystinosis, also called non-nephropathic cystinosis or benign cystinosis, is a rare inherited metabolic disorder that affects the eyes. It is the mildest form of cystinosis, a group of conditions caused by the buildup of an amino acid called cystine inside cells. In ocular cystinosis, cystine crystals accumulate mainly in the cornea (the clear front part of the eye), while the kidneys and other organs are typically spared. This sets it apart from the more severe infantile (nephropathic) form of cystinosis, which causes serious kidney damage early in life. People with ocular cystinosis

How is Ocular cystinosis inherited?

Ocular cystinosis follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Ocular cystinosis?

Yes — 2 recruiting clinical trials are currently listed for Ocular cystinosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Ocular cystinosis?

17 specialists and care centers treating Ocular cystinosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Ocular cystinosis?

2 patient support programs are currently tracked on UniteRare for Ocular cystinosis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.